Results 41 to 50 of about 4,708 (131)
Clinical and Translational Discovery, Volume 6, Issue 4, August 2026.Multi‐endpoint clinical trials face long‐standing statistical challenges. Vector‐based comparison (VBC) decomposes endpoints into orthogonal components. Applied to five clinical trials, it reduced confidence‐interval widths by about 50%, indicating higher statistical power, without altering the clinical meaning of endpoints.
Maria Kokkali, Vangelis D. Karalis
wiley +1 more source
Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles [PDF]
Clinical and Molecular Hepatology, 2022 Hung-Yao Lin, Tai-Chung Tseng
doaj +1 more source
Osteopenia in a young man associated with the use of tenofovir disoproxil fumarate
Clinical Case Reports, 2022 Tenofovir disoproxil fumarate is a recommended first‐line therapy for patients with chronic hepatitis B, although the frequent Tenofovir disoproxil fumarate related adverse drug reactions are nephrotoxicity and bone toxicity.
Chunmei Li, Hui Li, Ming Gong, Jia Wei
doaj +1 more source
Low-level viremia in nucleoside analog-treated chronic hepatitis B patients
Chinese Medical Journal, 2021 . Low-level viremia (LLV) was defined as persistent or intermittent episodes of detectable hepatitis B virus (HBV) DNA (
Qian Zhang +4 more
doaj +1 more source
Journal of the International AIDS Society, Volume 29, Issue 8, August 2026.Abstract Introduction The impact of pre‐exposure prophylaxis (PrEP) on the US HIV‐1 epidemic has not been fully maximized, potentially due to challenges in uptake, coverage, adherence and consistent use. Following the FDA (Food and Drug Adminstration) approval of twice‐yearly lenacapavir, epidemiological projections are needed to understand the ...
Mia Moore +11 more
wiley +1 more source
Journal of Virus Eradication, 2018 Background: Higher plasma tenofovir concentrations are associated with higher risks of renal and bone adverse events. The pharmacokinetic boosters ritonavir (RTV) and cobicistat (COBI) significantly increase plasma area under the curve (AUC ...
Andrew Hill +3 more
doaj +1 more source
Journal of Medical Virology, Volume 98, Issue 8, August 2026.ABSTRACT This study examined changes in anti‐Spike (anti‐S) antibodies (Abs) and type I interferon (IFN‐I) following the BNT162b2 vaccine in people living with HIV (PLWH) and analyzed the impact of demographic and immunological factors. In total, 75 PLWH and 28 healthy donors were followed at baseline (T0), at the second dose (T1), after the second ...
Federica Frasca +18 more
wiley +1 more source
Alimentary Pharmacology &Therapeutics, Volume 64, Issue 4, Page 517-526, August 2026.In 59,946 chronic hepatitis B patients followed over 23 years, COVID‐19 vaccination rollout was temporally associated with a 56% increase in HBsAg loss rates (peak 1.27 per 100 person‐years in 2022), followed by gradual waning. Negative control outcomes showed no similar pattern, supporting biological specificity. ABSTRACT Background and Aims Hepatitis
Jonggi Choi +6 more
wiley +1 more source
Hepatitis B Management in the Middle East: A Narrative Review of Current Antiviral Treatments
Gastrointestinal DisordersIntroduction: Chronic hepatitis B (CHB) is a significant public health issue worldwide, especially in the Middle East region. Around 8% to 20% of patients with CHB develop cirrhosis, which may progress to hepatocellular carcinoma.
Hannah Beck +6 more
doaj +1 more source
HIV Medicine, Volume 27, Issue 8, Page 1241-1252, August 2026.Abstract Introduction Two‐drug regimens (2DRs) may reduce long‐term drug toxicities and drug‐drug interactions for people with HIV (PWH) on antiretroviral therapy (ART). This study evaluated clinical and laboratory outcomes in PWH who switched from standard ART to dolutegravir and lamivudine (DTG + 3TC) in real‐world settings.
Tommy Hing‐cheung Tang +15 more
wiley +1 more source